136 related articles for article (PubMed ID: 18560223)
1. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Subramanian GM; Moore PA; Gowen BB; Olsen AL; Barnard DL; Paragas J; Hogan RJ; Sidwell RW
Chemotherapy; 2008; 54(3):176-80. PubMed ID: 18560223
[TBL] [Abstract][Full Text] [Related]
2. In vitro inhibition of SARS virus replication by human interferons.
Dahl H; Linde A; Strannegård O
Scand J Infect Dis; 2004; 36(11-12):829-31. PubMed ID: 15764169
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Sainz B; Mossel EC; Peters CJ; Garry RF
Virology; 2004 Nov; 329(1):11-7. PubMed ID: 15476870
[TBL] [Abstract][Full Text] [Related]
5. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG; Hage A; de Vries M; Valero-Jimenez AM; Schindewolf C; Dittmann M; Rajsbaum R; Menachery VD
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938761
[TBL] [Abstract][Full Text] [Related]
6. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Scagnolari C; Trombetti S; Alberelli A; Cicetti S; Bellarosa D; Longo R; Spanò A; Riva E; Clementi M; Antonelli G
Intervirology; 2007; 50(2):156-60. PubMed ID: 17191018
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Scagnolari C; Vicenzi E; Bellomi F; Stillitano MG; Pinna D; Poli G; Clementi M; Dianzani F; Antonelli G
Antivir Ther; 2004 Dec; 9(6):1003-11. PubMed ID: 15651759
[TBL] [Abstract][Full Text] [Related]
10. [Anti-SARS virus activities of different recombinant human interferons in cell culture system].
Duan ZJ; Zhang LL; Xie ZP; Yu ZA; Zhang LP; Zhang B; Liu YQ; Wang JW; Li WP; Zhang CH; Ma XJ; Shu YL; Duan SM; Li DX; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):205-8. PubMed ID: 15340558
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
12. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
Ströher U; DiCaro A; Li Y; Strong JE; Aoki F; Plummer F; Jones SM; Feldmann H
J Infect Dis; 2004 Apr; 189(7):1164-7. PubMed ID: 15031783
[TBL] [Abstract][Full Text] [Related]
13. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
Spiegel M; Pichlmair A; Mühlberger E; Haller O; Weber F
J Clin Virol; 2004 Jul; 30(3):211-3. PubMed ID: 15135736
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma).
Zheng B; He ML; Wong KL; Lum CT; Poon LL; Peng Y; Guan Y; Lin MC; Kung HF
J Interferon Cytokine Res; 2004 Jul; 24(7):388-90. PubMed ID: 15296649
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Kumaki Y; Day CW; Wandersee MK; Schow BP; Madsen JS; Grant D; Roth JP; Smee DF; Blatt LM; Barnard DL
Biochem Biophys Res Commun; 2008 Jun; 371(1):110-3. PubMed ID: 18406349
[TBL] [Abstract][Full Text] [Related]
17. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models.
Paragas J; Blatt LM; Hartmann C; Huggins JW; Endy TP
Antiviral Res; 2005 Jun; 66(2-3):99-102. PubMed ID: 15911026
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.
Morgenstern B; Michaelis M; Baer PC; Doerr HW; Cinatl J
Biochem Biophys Res Commun; 2005 Jan; 326(4):905-8. PubMed ID: 15607755
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin has a potent antiviral activity against SARS coronavirus.
Amici C; Di Caro A; Ciucci A; Chiappa L; Castilletti C; Martella V; Decaro N; Buonavoglia C; Capobianchi MR; Santoro MG
Antivir Ther; 2006; 11(8):1021-30. PubMed ID: 17302372
[TBL] [Abstract][Full Text] [Related]
20. Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.
Aguilar PV; Paessler S; Carrara AS; Baron S; Poast J; Wang E; Moncayo AC; Anishchenko M; Watts D; Tesh RB; Weaver SC
J Virol; 2005 Sep; 79(17):11300-10. PubMed ID: 16103182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
